Centre Hospitalier De Dieppe
- Address
- 19 Avenue Pasteur, Cs 20219, 76202 Dieppe, France
Bacterial Infections and Mycoses
The Intensive Care unit at Centre Hospitalier De Dieppe is conducting trials that address severe bacterial infections leading to sepsis and subsequent organ failure. One study evaluates high‑dose intravenous vitamin C to reduce mortality and persistent organ dysfunction, while another explores an adjunctive therapy for refractory shock.
- High‑dose vitamin C versus placebo in septic ARDS
- Adjunctive dexmedetomidine for refractory septic shock
These investigations aim to improve outcomes for critically ill patients with life‑threatening infections.
Respiratory Tract Diseases
Research in the respiratory domain focuses on patients with acute respiratory distress syndrome (ARDS) secondary to infection. The trials test interventions that may shorten mechanical ventilation time and protect lung function, including antioxidant therapy and sedation strategies.
- Vitamin C impact on ventilator dependence
- Dexmedetomidine effect on respiratory support
By targeting lung injury, the studies seek to enhance recovery and reduce intensive care stay.
General Critical Care
The site’s critical care program examines broader aspects of shock and organ support, encompassing both bacterial and undefined disease categories. Objectives include comparing mortality rates and the need for renal replacement or vasopressor support under novel treatment regimens.
- Composite endpoint of death or organ dysfunction
- 30‑day mortality with dexmedetomidine adjunct
Findings from these trials could inform best practices for managing severe systemic infections in ICU settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Dieppe
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Dexmedetomidine as Adjunctive Therapy for Refractory Septic Shock in Mechanically Ventilated Patients: A Randomized Controlled Trial | Hospices Civils De Lyon | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baricitinib | 2 | Unknown | 2016-02-19 | 2026-07-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.